Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions

J Neurochem. 1990 Jul;55(1):204-7. doi: 10.1111/j.1471-4159.1990.tb08839.x.

Abstract

DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein, Mr = 32,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) is a neuronal phosphoprotein that is enriched in neurons which possess dopamine D1 receptors, particularly striatonigral neurons. In rat brain slices, the phosphorylation state of DARPP-32 is regulated by dopamine, acting through the dopamine D1 receptor and the adenylyl cyclase system. This study reports that chronic blockade (21 days) of either dopamine D1 receptors by SCH-23390 or dopamine D2 receptors by raclopride does not affect the concentrations of DARPP-32 in specific rat brain regions (striatum, thalamus, hippocampus, frontal cerebral cortical pole). Northern blot analysis indicates that the steady-state level of DARPP-32 mRNA in striatum is also unchanged by these treatments.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Benzazepines / pharmacology*
  • Brain Chemistry / drug effects*
  • Dopamine / physiology*
  • Dopamine Antagonists
  • Dopamine and cAMP-Regulated Phosphoprotein 32
  • Male
  • Nerve Tissue Proteins / analysis*
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Osmolar Concentration
  • Phosphoproteins / metabolism
  • RNA, Messenger / metabolism*
  • Raclopride
  • Rats
  • Rats, Inbred Strains
  • Salicylamides / pharmacology*

Substances

  • Benzazepines
  • Dopamine Antagonists
  • Dopamine and cAMP-Regulated Phosphoprotein 32
  • Nerve Tissue Proteins
  • Phosphoproteins
  • RNA, Messenger
  • Salicylamides
  • Raclopride
  • Dopamine